




## Supporting Information




**Figure S1.** Sensitivity analysis with respect to fish intake and CVD mortality risk. Sensitivity analysis did not change the results. CVD, cardiovascular disease.



**Figure S2.** Sensitivity analysis with respect to marine n-3 PUFA intake and CVD mortality risk. The negative association between marine n-3 PUFA and risk of CVD mortality was altered from 0.87 (0.85-0.89) to 0.84 (0.81-0.87) by deleting the study of Zhuang2019. n-3 PUFA, n-3 polyunsaturated fatty acids; CVD, cardiovascular disease.



**Figure S3.** Funnel plot of the RR of 18 articles on fish intake and CVD mortality risk. No evidence of publication bias was noted. RR, relative risk; CVD, cardiovascular disease.



**Figure S4.** Funnel plot of the RR of 10 articles on marine n-3 PUFA intake and CVD mortality risk. No evidence of publication bias was noted. RR, relative risk; n-3 PUFA, n-3 polyunsaturated fatty acids; CVD, cardiovascular disease.

**Table S1.** Quality assessment of studies investigating fish intake and CVD mortality risk.

Study	Representativen ess of the Expose d Cohort	Selection of the Non exposed Co hort		Ascertainme nt of Exposu re	Demonstration that O utcome of Interest at S tart of Study	Comparability of Cohorts on the Basis of the Desig n or Analysis	Assessment of outcome	Follow-Up Long Enough for the Outcomes to Oc cur	Adequacy of F ollow-Up of Co horts	Grades
Mohan 2021	-	☆	☆	-		★★	☆	-	☆	★★★★
Kobayashi20 19	☆	☆	☆	☆		★★	☆	☆	☆	★★★★
Kondo 2019	☆	☆	☆	☆		☆	☆	☆	☆	★★★★
Van den brandt 2019	☆	☆	☆	☆		★★	☆	☆	☆	★★★★
Deng2 018	☆	☆	☆	-		★★	☆	☆	-	★★★
Henge	☆	☆	☆	☆		★★	☆	☆	☆	★★★★

---

veld20										☆☆☆☆
18										☆
Zhang 2018	☆	☆	☆	☆	☆☆	☆	☆	-		☆☆☆☆
Bellavi a2017	☆	☆	☆	☆	☆☆	☆	☆	☆	☆	☆☆☆☆
Nahab 2016	☆	☆	☆	☆	☆☆	☆	-	-		☆☆☆☆
Owen2 016	☆	☆	☆	-	☆☆	☆	-	☆		☆☆☆☆
Eguchi 2014	☆	☆	☆	☆	☆☆	☆	☆	-		☆☆☆☆
Takata 2013	☆	☆	☆	-	☆	☆	-	☆		☆☆☆☆
Tomas allo201 0				-	☆	☆	☆	☆	☆	☆☆☆☆
Yamag	☆	☆	☆	☆	☆	☆	☆	-		☆☆☆☆

---

---

ishi200										★★★☆
8										
Folso	☆	☆	☆	-	★★	☆	☆	-		★★★★
m2004										★★★☆
Gillum	☆	☆	☆	☆	★★	☆	☆	☆		★★★★
2000										☆
Albert	-	☆	☆	☆	★★	☆	☆	☆		★★★★
1998										★★★★
Davigl	☆	☆	☆	-	★★	☆	☆	☆		★★★★
us1997										★★★★

---

CVD, cardiovascular disease

**Table S2.** Quality assessment of studies investigating marine n-3 PUFA intake and CVD mortality risk.

Study	Representativeness of the Exposed Cohort	Selection of the Non-exposed Cohort	Ascertainment of Exposure	Demonstration that Outcome of Interest at Start of Study	Comparability of Cohorts on the Basis of the Design of Study	Assessment of outcome	Follow-Up Long Enough for the Outcomes to Occur		Adequacy of Follow-Up of Cohorts	Grades
<b>Donat-Varga2020</b>										
	☆	☆	☆	☆	☆☆	☆	☆	-	☆☆☆☆☆☆☆☆	
Zhuang2019	☆	☆	☆	-	☆☆	☆	☆	☆	☆☆☆☆☆☆☆☆	
Zhang2018	☆	☆	☆	☆	☆☆	☆	☆	-	☆☆☆☆☆☆☆☆	
Rhee2016	☆	☆	☆	☆	☆☆	☆	☆	☆	☆☆☆☆☆☆☆☆	
Owen2016	☆	☆	☆	-	☆☆	☆	-	☆	☆☆☆☆☆☆☆	
Miyagawa2014	☆	☆	☆	☆	☆	☆	☆	-	☆☆☆☆☆☆☆	
Bell2014	☆	☆	☆	-	☆	☆	-	☆	☆☆☆☆☆	
Koh2013	☆	☆	☆	-	☆☆	☆	☆	☆	☆☆☆☆☆☆☆	
Takata2013	☆	☆	☆	-	☆	☆	-	☆	☆☆☆☆☆	
Kamphuis2006	☆	☆	☆	☆	☆☆	☆	☆	-	☆☆☆☆☆☆☆	

CVD, cardiovascular disease